Lack of association between FTO gene variations and metabolic healthy obese (MHO) phenotype: Tehran Cardio-metabolic Genetic Study (TCGS).
Adult
Aged
Alpha-Ketoglutarate-Dependent Dioxygenase FTO
/ genetics
Blood Glucose
/ metabolism
Case-Control Studies
Female
Genetic Association Studies
Genetic Predisposition to Disease
Genotype
Humans
Lipids
/ blood
Male
Middle Aged
Obesity, Metabolically Benign
/ genetics
Phenotype
Polymorphism, Single Nucleotide
Young Adult
Cholesteryl ester transfer protein
Fat mass and obesity-associated protein
Metabolic syndrome
Obesity
Journal
Eating and weight disorders : EWD
ISSN: 1590-1262
Titre abrégé: Eat Weight Disord
Pays: Germany
ID NLM: 9707113
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
11
11
2017
accepted:
21
02
2018
pubmed:
12
3
2018
medline:
18
11
2020
entrez:
12
3
2018
Statut:
ppublish
Résumé
Obesity is currently an international epidemic and metabolic derangements pose these individuals at greater risk for future morbidity and mortality. Genetics and environmental factors have undeniable effects and among genetic risk factors, FTO/CETP genes are important. The current study examines the interaction between obesity phenotypes and FTO/CETP SNPs and their effects on lipid profile changes. We selected 954 adult subjects from TCGS (47.9% male). Participants were stratified according to their BMI and presence of metabolic syndrome according to the Joint Interim Statement (JIS) definition. Nine selected polymorphisms from FTO/CETP genes were genotyped using Tetra ARMS-PCR method. After age and sex adjustment the interaction of 9 markers with lipid profiles among phenotypes were tested by PASW. In three main groups, HDL_C level had a strong significant association with CETP markers: (rs3764261, β(95% CI) - 0.48(- 0.61 to - 0.35), P = 1.0 × 10 In the present study, we investigated the association between obesity phenotypes and some variations in FTO/CETP genes for the first time. Our study showed that four markers in the first intron of the FTO gene should be the risk marker in MUHO participants. Level III, case-control study.
Sections du résumé
BACKGROUND
BACKGROUND
Obesity is currently an international epidemic and metabolic derangements pose these individuals at greater risk for future morbidity and mortality. Genetics and environmental factors have undeniable effects and among genetic risk factors, FTO/CETP genes are important. The current study examines the interaction between obesity phenotypes and FTO/CETP SNPs and their effects on lipid profile changes.
MATERIALS AND METHODS
METHODS
We selected 954 adult subjects from TCGS (47.9% male). Participants were stratified according to their BMI and presence of metabolic syndrome according to the Joint Interim Statement (JIS) definition. Nine selected polymorphisms from FTO/CETP genes were genotyped using Tetra ARMS-PCR method. After age and sex adjustment the interaction of 9 markers with lipid profiles among phenotypes were tested by PASW.
RESULTS
RESULTS
In three main groups, HDL_C level had a strong significant association with CETP markers: (rs3764261, β(95% CI) - 0.48(- 0.61 to - 0.35), P = 1.0 × 10
CONCLUSION
CONCLUSIONS
In the present study, we investigated the association between obesity phenotypes and some variations in FTO/CETP genes for the first time. Our study showed that four markers in the first intron of the FTO gene should be the risk marker in MUHO participants.
LEVEL OF EVIDENCE
METHODS
Level III, case-control study.
Identifiants
pubmed: 29525920
doi: 10.1007/s40519-018-0493-2
pii: 10.1007/s40519-018-0493-2
doi:
Substances chimiques
Blood Glucose
0
Lipids
0
Alpha-Ketoglutarate-Dependent Dioxygenase FTO
EC 1.14.11.33
FTO protein, human
EC 1.14.11.33
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25-35Subventions
Organisme : Iran National Scientific Foundation
ID : 93017278
Références
Bioinformatics. 2005 May 1;21(9):2128-9
pubmed: 15705655
JMIR Res Protoc. 2017 Feb 23;6(2):e28
pubmed: 28232301
Nucleic Acids Res. 1988 Feb 11;16(3):1215
pubmed: 3344216
Trials. 2009 Jan 25;10:5
pubmed: 19166627
Eur J Clin Invest. 2011 Oct;41(10):1105-12
pubmed: 21443751
Arch Iran Med. 2010 May;13(3):243-4
pubmed: 20433230
Soz Praventivmed. 2002;47(6):408-26
pubmed: 12643001
Ann Intern Med. 2013 Dec 3;159(11):758-69
pubmed: 24297192
Nat Genet. 2012 Feb 19;44(3):302-6
pubmed: 22344221
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
J Nutrigenet Nutrigenomics. 2011;4(4):222-38
pubmed: 22056736
BMC Med Genet. 2008 Sep 17;9:85
pubmed: 18799002
J Diabetes Complications. 2013 Jul-Aug;27(4):346-50
pubmed: 23490278
PLoS One. 2014 Jun 09;9(6):e98984
pubmed: 24911064
Nature. 2000 Jul 13;406(6792):203-7
pubmed: 10910363
Tex Heart Inst J. 2011;38(2):160-2
pubmed: 21494527
Lipids Health Dis. 2010 May 21;9:52
pubmed: 20487572
Nat Genet. 2007 Jul;39(7):875-81
pubmed: 17558409
Eur J Endocrinol. 2011 Mar;164(3):381-8
pubmed: 21147891
Science. 2007 May 11;316(5826):889-94
pubmed: 17434869
J Clin Endocrinol Metab. 2006 Aug;91(8):2906-12
pubmed: 16735483
Nat Genet. 2012 Feb 19;44(3):307-11
pubmed: 22344219
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
PLoS Genet. 2013;9(1):e1003171
pubmed: 23341774
Nat Genet. 2013 Nov;45(11):1274-1283
pubmed: 24097068
Science. 2007 Nov 30;318(5855):1469-72
pubmed: 17991826
Nat Genet. 2009 May;41(5):527-34
pubmed: 19396169
Genome Med. 2013 Jun 28;5(6):55
pubmed: 23806069
J Clin Endocrinol Metab. 2004 Jun;89(6):2569-75
pubmed: 15181025
Am J Physiol Regul Integr Comp Physiol. 2008 Apr;294(4):R1185-96
pubmed: 18256137
N Engl J Med. 1998 Jan 8;338(2):86-93
pubmed: 9420339